- Datum30.06.2025
- Uhrzeit08:00 - 09:00 Uhr
- Veranstalter
XTB
Altan Cantürk
Moderator
Solid Biosciences Aktie
Verkaufen
Kaufen
Solid Biosciences Chart
Solid Biosciences Realtime-Kurs
| Handelsplatz | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
|---|---|---|---|---|---|---|
| Nasdaq | VK | |||||
| Nasdaq Basic | VK | |||||
| Cboe BZX | VK |
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Keine Ergebnisse gefunden
Wertentwicklung (Nasdaq)
-1,87 %
Intraday
-1,46 %
1 Woche
44,79 %
1 Monat
18,00 %
Seit Jahresbeginn
-16,75 %
1 Jahr
-50,35 %
3 Jahre
-90,10 %
5 Jahre
Passender Service zu Solid Biosciences
Webinar zu Solid Biosciences
Kursinformationen (Nasdaq)
- Tagestief / Hoch ($)-
- 52W-Tief / Hoch ($)2,410-10,370
- Jahrestief / Hoch ($)2,410-7,200
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von Solid Biosciences
Keine Dividenden verfügbar
Termine von Solid Biosciences
Keine aktuellen Termine
Beschreibung
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
